outraged prices gilead sciences charges medicines aids advocacy organization succeeded placing called unique resolution drug companys shareholders proposal ties compensation chief executive john martin wider access drug makers popular roster hiv hepatitis c treatments
shareholder resolution aids healthcare foundation previously lambasted gilead drug makers pricing proposed response recently approved sovaldi pill hepatitis c gilead priced medicine 8400 12week treatment works 100 day result ahf maintains sovaldi unaffordable patients
concerns fact prompted us house energy commerce committee ask gilead explain rationale behind pricing letter sent yesterday drug maker lawmakers worry sovaldi pricing may high patients public private insurance report released last week institute clinical economic review nonprofit supported part insurers forecast sovaldi may negatively burden healthcare budgets
jump
